Search

Copyright of Advances in Laboratory Medicine / Avances en Medicina de Laboratorio is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Colombian Journal of Nephrology / Revista Colombiana de Nefrología is the property of Colombian Association of Nephrology & Hypertension and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

INTRODUCTION: The hemolytic uremic syndrome in its atypical variety is a rare thrombotic microangiopathy, with high morbidity and mortality if a timely diagnosis is not available to allow an adequate specific treatment. CLINICAL CASE: Patient with a confirmed diagnosis of atypical hemolytic uremic syndrome treated with eculizumab with total remission and satisfactory clinical evolution. Diagnostic suspicion is important for early and specific treatment and favorable prognosis. CONCLUSION: The case reported here is illustrative of the clinical presentation of the atypical haemolytic uraemic syndrome. Its evolution was torpid, despite the treatment with plasma infusion and plasmapheresis and its total remission with eculizumab. In Mexico, few cases have been confirmed, only in some cases has the specific treatment been administered. [ABSTRACT FROM AUTHOR]

Copyright of Medicina (Buenos Aires) is the property of Medicina (Buenos Aires) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The atypical hemolytic uremic syndrome (aHUS) consists on hemolytic anemia, microangiopathy, thrombocytopenia and renal failure. It happens as a result of a genetic disorder that leads to the deregulation of the alternative complement pathway on the cells surfaces. A case of a 34-year-old kidney transplanted male suffering aHUS secondary to human parvovirus B19 is presented. After plasma exchange therapy, the anemia and renal function normalized without starting treatment with eculizumab. [ABSTRACT FROM AUTHOR]

Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Introducción El Síndrome Hemolítico Urémico atípico (SHUa) mediado por complemento es una microangiopatía trombótica caracterizada por anemia hemolítica, trombocitopenia y falla renal. En el embarazo es una condición rara, con una prevalencia de 1 por cada 25.0000 gestaciones, sin embargo cuenta con una elevada morbimortalidad. Reporte de caso Paciente de 29 años con embarazo de 32,1 semanas, con antecedente no claro de microangiopatía trombótica, quien ingresa por cuadro de equimosis en extremidades superiores e inferiores, gingivorragia, hematuria y cifras tensionales en estadio I. Al ingreso se documenta elevación de LDH (994), proteinuria aislada significativa (500), trombocitopenia (8000) y evidencia ecográfica de peso en percentil 6 además de Arteria cerebral media e índice cerebroplacentario menor al percentil 5, por lo que se considera finalización de gestación por sospecha de Síndrome de HELLP incompleto superpuesto a patología de base. Requirió manejo en UCI con soporte transfusional y manejo conjunto con Hematología quienes indican Inmunoglobulina humana, corticoides y solicitan ADAMTS 13. Pese a manejo la paciente persiste con trombocitopenia refractaria, LDH elevada y anemia hemolítica progresiva por lo que indican inicio de plasmaféresis a cargo de servicio de Nefrología con mejoría parcial. Reporte de ADAMTS 13 normal, estudio inmunológico negativo con lo cual se descarta PTT, y dado compromiso renal por proteinuria, hematuria e HTA se sospecha SHUa, indican Eculizumab con mejoría progresiva del cuadro clínico y es posible dar de alta con manejo y seguimiento. Se indicó estudio genético el cual se encuentra pendiente. Discusión Se estima que el Síndrome Hemolítico Urémico atípico (SHUa) ocurre en un 40% en el embarazo y hasta un 80% durante el puerperio, tan solo un pequeño porcentaje se complica con Preeclampsia. Se ha considerado el embarazo como desencadenante de ésta enfermedad sin embargo el mecanismo por el cual lo realiza aún no se encuentra claro. El manejo tradicional descrito incluye soporte dialítico, transfusional y plasmaféresis, sin embargo hay evidencia creciente en la eficacia del uso Inhibidor de C5- Eculizumab de manera satisfactoria en el embarazo en limitados reportes de caso. El enfoque inicial en una gestante que presente anemia, trombocitopenia y compromiso renal es en primera instancia las condiciones relacionadas con el embarazo como los son la Preeclampsia y el Síndrome de HELLP; posteriormente deben sospecharse las diferentes Microangiopatías Trombóticas (MAT). El diagnóstico y tratamiento oportuno permitirán disminuir la alta morbimortalidad materna y fetal. En caso de que se sospeche una MAT, se deben medir los niveles de actividad de ADAMTS 13 para su diferenciación y tratamiento oportuno6. En este reporte de caso presentamos una paciente quien curso con una Preeclampsia con criterios de severidad junto con una Microangiopatía Trombótica de base con pobre respuesta al manejo medico inicial instaurado, con niveles de ADAMTS13 normales, que permitió diferenciar una PTT de un SHUa, y así dar inicio de manejo con Eculizumab con adecuada respuesta clínica. [ABSTRACT FROM AUTHOR]